Lymphatic Malformations Stocks

Biopharmaceutical and medical technology firms in this cohort focus on diagnosing and treating disorders of the lymphatic system, ranging from chronic lymphedema management to rare congenital vascular malformations.

As of Oct 23, 2026, Lymphatic Malformations has 4 US-listed companies worth $2.4B combined. The median member moved +3.5% over the past week; TCMD led at +5.0% and TARA trailed at +0.4%.

Companies in Lymphatic Malformations

• PVLA – Palvella Therapeutics, Inc, $1.7B
• TCMD – Tactile Systems Technology Inc, $501M
• TARA – Protara Therapeutics Inc, $137M
• QNRX – Quoin Pharmaceuticals Ltd DRC, $21.9M

Related groups

• Dermatology
• Rare Diseases
• Clinical Stage Biotech
• Clinical Stage
• Healthcare
• Biotechnology
• Biopharmaceutical

All equity groups